Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AVTE NASDAQ:ELYM NASDAQ:LWAC NASDAQ:SBTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVTEAerovate Therapeutics$24.52+1.2%$16.97$89.95▼$99.05$710.71M0.9553,591 shs538,974 shsELYMEliem Therapeutics$9.69+8.8%$7.53$2.35▼$11.55$288.30M-0.39486,688 shs819,804 shsLWACLightWave Acquisition$10.18$10.15$9.81▼$10.20$306.16MN/A6,931 shs622 shsSBTXSilverback Therapeutics$8.56+3.6%$8.40$2.80▼$8.97$308.66M0.6337,931 shs1.49 million shsThe 7 Hottest IPOs On Wall Street’s 2026 WatchlistMarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVTEAerovate Therapeutics0.00%-3.00%+56.42%+45.53%+94.15%ELYMEliem Therapeutics0.00%-2.52%+35.82%+99.33%+601.57%LWACLightWave Acquisition0.00%0.00%-0.25%+0.74%-33.10%SBTXSilverback Therapeutics0.00%+3.26%+3.13%-14.31%-40.80%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVTEAerovate Therapeutics$24.52+1.2%$16.97$89.95▼$99.05$710.71M0.9553,591 shs538,974 shsELYMEliem Therapeutics$9.69+8.8%$7.53$2.35▼$11.55$288.30M-0.39486,688 shs819,804 shsLWACLightWave Acquisition$10.18$10.15$9.81▼$10.20$306.16MN/A6,931 shs622 shsSBTXSilverback Therapeutics$8.56+3.6%$8.40$2.80▼$8.97$308.66M0.6337,931 shs1.49 million shsThe 7 Hottest IPOs On Wall Street’s 2026 WatchlistMarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVTEAerovate Therapeutics0.00%-3.00%+56.42%+45.53%+94.15%ELYMEliem Therapeutics0.00%-2.52%+35.82%+99.33%+601.57%LWACLightWave Acquisition0.00%0.00%-0.25%+0.74%-33.10%SBTXSilverback Therapeutics0.00%+3.26%+3.13%-14.31%-40.80%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAVTEAerovate Therapeutics 0.00N/AN/AN/AELYMEliem Therapeutics 0.00N/AN/AN/ALWACLightWave Acquisition 1.00SellN/AN/ASBTXSilverback Therapeutics 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest SBTX, AVTE, LWAC, and ELYM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/1/2026LWACLightWave Acquisition Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)(Data available from 5/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAVTEAerovate TherapeuticsN/AN/AN/AN/A$3.96 per shareN/AELYMEliem TherapeuticsN/AN/AN/AN/A$3.90 per shareN/ALWACLightWave AcquisitionN/AN/AN/AN/AN/AN/ASBTXSilverback TherapeuticsN/AN/AN/AN/A$7.41 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAVTEAerovate Therapeutics-$75.52M-$1.70N/AN/AN/AN/A-90.19%-77.47%N/AELYMEliem Therapeutics-$35.12M-$0.53N/AN/AN/AN/A-47.03%-45.97%N/ALWACLightWave AcquisitionN/AN/AN/AN/AN/AN/AN/AN/AN/ASBTXSilverback Therapeutics-$89.48M-$2.42N/AN/AN/AN/A-29.62%-28.20%N/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAVTEAerovate TherapeuticsN/AN/AN/AN/AN/AELYMEliem TherapeuticsN/AN/AN/AN/AN/ALWACLightWave AcquisitionN/AN/AN/AN/AN/ASBTXSilverback TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAVTEAerovate TherapeuticsN/A8.788.78ELYMEliem TherapeuticsN/A60.4160.41LWACLightWave AcquisitionN/AN/AN/ASBTXSilverback TherapeuticsN/A67.8767.87Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAVTEAerovate TherapeuticsN/AELYMEliem Therapeutics69.76%LWACLightWave AcquisitionN/ASBTXSilverback Therapeutics74.89%Insider OwnershipCompanyInsider OwnershipAVTEAerovate Therapeutics24.90%ELYMEliem Therapeutics4.70%LWACLightWave AcquisitionN/ASBTXSilverback Therapeutics34.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAVTEAerovate Therapeutics2028.99 million21.69 millionOptionableELYMEliem Therapeutics929.75 million28.35 millionNot OptionableLWACLightWave AcquisitionN/A30.08 millionN/ANot OptionableSBTXSilverback Therapeutics8336.06 million23.65 millionNot OptionableSBTX, AVTE, LWAC, and ELYM HeadlinesRecent News About These CompaniesSilverback Therapeutics (NASDAQ:SBTX) Trading Down 0.1% - Here's What HappenedApril 28, 2026 | marketbeat.comMeet the Silverback, the Leader of the TroopOctober 17, 2024 | pbs.orgP10 Fun Facts About Mountain GorillasSeptember 18, 2024 | nationalgeographic.comNCapstanTx secures $165 million to deliver precise in vivo cell engineeringJuly 28, 2024 | pharmaphorum.comPARS Pharmaceuticals Inc (SPRY)May 11, 2023 | uk.investing.comWild IslesMarch 12, 2023 | wwf.org.ukWA look back at RNA Therapeutics – day oneFebruary 23, 2023 | pharmaphorum.comPSPRY ARS Pharmaceuticals, Inc.January 24, 2023 | seekingalpha.comARS Pharma CEO Richard Lowenthal Holds 8% Silverback Stake After MergerNovember 22, 2022 | 247wallst.comDr. Sarina Tanimoto Discloses Position in SBTX / Silverback TherapeuticsNovember 18, 2022 | nasdaq.comARS Pharmaceuticals Announces Presentation of Clinical Data Supporting neffy® (epinephrine nasal spray) for the Treatment of Allergic Reactions (Type I) including AnaphylaxisNovember 10, 2022 | finance.yahoo.comARS Pharmaceuticals Closes Merger with Silverback TherapeuticsNovember 8, 2022 | finance.yahoo.comSilverback : FDA Accepts ARS Pharm's NDA For Neffy For Treatment Of Allergic ReactionsOctober 28, 2022 | markets.businessinsider.comFDA accepts ARS Pharma’s NDA for NeffyOctober 24, 2022 | thepharmaletter.comTSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates HIL, SBTX, COWN, AERIOctober 23, 2022 | kentuckytoday.comKSilverback Therapeutics, Inc. announces the FDA’s acceptance of ARS Pharmaceuticals’ NDA for neffy® (epinephrine nasal spray) for the Treatment of Allergic Reactions (type I) including AnaphylaxisOctober 21, 2022 | finance.yahoo.comIs Silverback Therapeutics Inc (SBTX) Stock a Good Investment?October 19, 2022 | aaii.comASHAREHOLDER ALERT: The M&A Class Action Firm is Investigating the Merger – RFP, SBTX, AAWW, COWNOctober 12, 2022 | bakersfield.comBINVESTIGATION ALERT: Halper Sadeh LLC Investigates CVET, SBTX, IRBTSeptember 17, 2022 | markets.businessinsider.comSBTX Silverback Therapeutics, Inc.September 15, 2022 | seekingalpha.comSHAREHOLDER NOTICE: Halper Sadeh LLP Investigates FTAI, SBTX, CVET, GBTSeptember 6, 2022 | markets.businessinsider.comMedia Sentiment Over TimeSBTX, AVTE, LWAC, and ELYM Company DescriptionsAerovate Therapeutics NASDAQ:AVTE$24.52 +0.29 (+1.20%) As of 05/4/2026Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. The company was incorporated in 2018 and is headquartered in Waltham, Massachusetts.Eliem Therapeutics NASDAQ:ELYM$9.69 +0.78 (+8.75%) As of 05/4/2026Eliem Therapeutics, Inc., a biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems. The company was incorporated in 2018 and is headquartered in Wilmington, Delaware.LightWave Acquisition NASDAQ:LWAC$10.18 0.00 (0.00%) Closing price 03:59 PM EasternExtended Trading$10.18 0.00 (-0.05%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Locust Walk Acquisition Corp. does not have significant operations. It intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was incorporated in 2020 and is based in Boston, Massachusetts.Silverback Therapeutics NASDAQ:SBTX$8.56 +0.30 (+3.63%) As of 05/1/2026Silverback Therapeutics, Inc., a biopharmaceutical company, develops tissue-targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. The company offers SBT8230 to treat chronic hepatitis B virus infection by eliciting an anti-viral immune response by targeting TLR8 activation to the liver. Silverback Therapeutics, Inc. was incorporated in 2016 and is headquartered in Seattle, Washington. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir Drops After a Blowout Q1—What Investors Should Know Shopify’s Valuation Crisis Creates Opportunity in 2026 onsemi Stock Dips After Earnings: Why the Dip Is Buyable TSLA: 3 Reasons the Stock Could Hit $400 in May Nebius Breaks Out to All-Time Highs—Here's What's Driving It. 3 Reasons Analysts Love DexCom The Great Chip Divide: AI Chip War Pivots from Hype to Execution Atomic Dividends: Big Tech's New Energy Bet Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
